Cross talk between smooth muscle cells and monocytes/activated monocytes via CX3CL1/CX3CR1 axis augments expression of pro-atherogenic molecules

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 12, 2011, Pages 2026-2035

  Butoi, Elena Dragomir ^a   Gan, Ana Maria ^a   Manduteanu, Ileana ^a   Stan, Daniela ^a   Calin, Manuela ^a,c   Pirvulescu, Monica ^a   Koenen, Rory Ryan ^b   Weber, Christian ^b   Simionescu, Maya ^a  

^a INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c PETRU PONI INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Romania)

Author keywords

CX3CR1; Fractalkine; Inflammatory cytokine; Metalloproteinase; Monocyte; Smooth muscle cell

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL ACTIVATION; CELL INTERACTION; CELL TYPE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; INCUBATION TEMPERATURE; INFLAMMATION; MOLECULAR INTERACTION; MONOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SMOOTH MUSCLE FIBER; UPREGULATION;

AORTA; BLOTTING, WESTERN; CELLS, CULTURED; CHEMOKINE CX3CL1; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MONOCYTES; MUSCLE, SMOOTH, VASCULAR; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 80053436529     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.08.009     Document Type: Article

References (44)

1. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
2. Hansson G.K., Libby P., Schonbeck U., Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 2002, 91:281-291.
3. Weber C., Schober A., Zernecke A. Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1997-2008.
4. Muller-Werdan U., Schumann H., Loppnow H., Fuchs R., Darmer D., Stadler J., Holtz J., Werdan K. Endotoxin and tumor necrosis factor alpha exert a similar proinflammatory effect in neonatal rat cardiomyocytes, but have different cardiodepressant profiles. J. Mol. Cell. Cardiol. 1998, 30:1027-1036.
5. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
6. Ohta H., Wada H., Niwa T., Kirii H., Iwamoto N., Fujii H., Saito K., Sekikawa K., Seishima M. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 2005, 180:11-17.
7. Elhage R., Maret A., Pieraggi M.T., Thiers J.C., Arnal J.F., Bayard F. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation 1998, 97:242-244.
8. Kleemann R., Zadelaar S., Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc. Res. 2008, 79:360-376.
9. Huber S.A., Sakkinen P., Conze D., Hardin N., Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 1999, 19:2364-2367.
10. Galis Z.S., Sukhova G.K., Kranzhofer R., Clark S., Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:402-406.
11. Morishige K., Shimokawa H., Matsumoto Y., Eto Y., Uwatoku T., Abe K., Sueishi K., Takeshita A. Overexpression of matrix metalloproteinase-9 promotes intravascular thrombus formation in porcine coronary arteries in vivo. Cardiovasc. Res. 2003, 57:572-585.
12. Doran A.C., Meller N., McNamara C.A. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2008, 28:812-819.
13. Zhu Y., Hojo Y., Ikeda U., Takahashi M., Shimada K. Interaction between monocytes and vascular smooth muscle cells enhances matrix metalloproteinase-1 production. J. Cardiovasc. Pharmacol. 2000, 36:152-161.
14. Fong A.M., Robinson L.A., Steeber D.A., Tedder T.F., Yoshie O., Imai T., Patel D.D. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J. Exp. Med. 1998, 188:1413-1419.
15. Lucas A.D., Bursill C., Guzik T.J., Sadowski J., Channon K.M., Greaves D.R. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 2003, 108:2498-2504.
16. Cai Q., Lanting L., Natarajan R. Growth factors induce monocyte binding to vascular smooth muscle cells: implications for monocyte retention in atherosclerosis. Am. J. Physiol. Cell Physiol. 2004, 287:C707-C714.
17. Barlic J., Zhang Y., Murphy P.M. Atherogenic lipids induce adhesion of human coronary artery smooth muscle cells to macrophages by up-regulating chemokine CX3CL1 on smooth muscle cells in a TNFalpha-NFkappaB-dependent manner. J. Biol. Chem. 2007, 282:19167-19176.
18. Lesnik P., Haskell C.A., Charo I.F. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J. Clin. Invest. 2003, 111:333-340.
19. McDermott D.H., Fong A.M., Yang Q., Sechler J.M., Cupples L.A., Merrell M.N., Wilson P.W., D'Agostino R.B., O'Donnell C.J., Patel D.D., Murphy P.M. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J. Clin. Invest. 2003, 111:1241-1250.
20. Dragomir E., Manduteanu I., Calin M., Gan A.M., Stan D., Koenen R.R., Weber C., Simionescu M. High glucose conditions induce upregulation of fractalkine and monocyte chemotactic protein-1 in human smooth muscle cells. Thromb. Haemost. 2008, 100:1155-1165.
21. Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Cardiovasc. Res. 1997, 35:2-3. W.M. Association.
22. Tirziu D., Jinga V.V., Serban G., Simionescu M. The effects of low density lipoproteins modified by incubation with chondroitin 6-sulfate on human aortic smooth muscle cells. Atherosclerosis 1999, 147:155-166.
23. C.E., Popov D., Shepherd P.R. High glucose-induced alterations in human aortic smooth muscle cells: phenotypic changes and signal transduction mediators. Proc. Rom. Acad. B 2004, 6:47-51.
24. Raicu M., Florea S. Deleterious effects of nifedipine on smooth muscle cells implies alterations of intracellular calcium signaling. Fundam. Clin. Pharmacol. 2001, 15:387-392.
25. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
26. Chandrasekar B., Mummidi S., Perla R.P., Bysani S., Dulin N.O., Liu F., Melby P.C. Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem. J. 2003, 373:547-558.
27. Barlic J., Zhang Y., Foley J.F., Murphy P.M. Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor gamma-dependent pathway. Circulation 2006, 114:807-819.
28. Newby A.C. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler. Thromb. Vasc. Biol. 2008, 28:2108-2114.
29. Shames B.D., Selzman C.H., Pulido E.J., Meng X., Meldrum D.R., McIntyre R.C., Harken A.H., Banerjee A. LPS-induced NF-kappaB activation and TNF-alpha release in human monocytes are protein tyrosine kinase dependent and protein kinase C independent. J. Surg. Res. 1999, 83:69-74.
30. Chen L., Frister A., Wang S., Ludwig A., Behr H., Pippig S., Li B., Simm A., Hofmann B., Pilowski C., Koch S., Buerke M., Rose-John S., Werdan K., Loppnow H. Interaction of vascular smooth muscle cells and monocytes by soluble factors synergistically enhances IL-6 and MCP-1 production. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H987-H996.
31. Mangge H., Hubmann H., Pilz S., Schauenstein K., Renner W., Marz W. Beyond cholesterol-inflammatory cytokines, the key mediators in atherosclerosis. Clin. Chem. Lab. Med. 2004, 42:467-474.
32. Li Z., Song T., Liu G.Z., Liu L.Y. Inhibitory effects of cariporide on LPC-induced expression of ICAM-1 and adhesion of monocytes to smooth muscle cells in vitro. Acta Pharmacol. Sin. 2006, 27:1326-1332.
33. Newby A.C. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc. Res. 2006, 69:614-624.
34. Cho A., Graves J., Reidy M.A. Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2000, 20:2527-2532.
35. Greaves D.R., Hakkinen T., Lucas A.D., Liddiard K., Jones E., Quinn C.M., Senaratne J., Green F.R., Tyson K., Boyle J., Shanahan C., Weissberg P.L., Gordon S., Yla-Hertualla S. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 2001, 21:923-929.
36. Cai Q., Lanting L., Natarajan R. Interaction of monocytes with vascular smooth muscle cells regulates monocyte survival and differentiation through distinct pathways. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2263-2270.
37. Ludwig A., Berkhout T., Moores K., Groot P., Chapman G. Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. J. Immunol. 2002, 168:604-612.
38. de Winther M.P., Kanters E., Kraal G., Hofker M.H. Nuclear factor kappaB signaling in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2005, 25:904-914.
39. Green S.R., Han K.H., Chen Y., Almazan F., Charo I.F., Miller Y.I., Quehenberger O. The CC chemokine MCP-1 stimulates surface expression of CX3CR1 and enhances the adhesion of monocytes to fractalkine/CX3CL1 via p38 MAPK. J. Immunol. 2006, 176:7412-7420.
40. Saitoh Y., Koizumi K., Sakurai H., Minami T., Saiki I. RANKL-induced down-regulation of CX3CR1 via PI3K/Akt signaling pathway suppresses Fractalkine/CX3CL1-induced cellular responses in RAW264.7 cells. Biochem. Biophys. Res. Commun. 2007, 364:417-422.
41. Cambien B., Pomeranz M., Millet M.A., Rossi B., Schmid-Alliana A. Signal transduction involved in MCP-1-mediated monocytic transendothelial migration. Blood 2001, 97:359-366.
42. Zhu W., Downey J.S., Gu J., Di Padova F., Gram H., Han J. Regulation of TNF expression by multiple mitogen-activated protein kinase pathways. J. Immunol. 2000, 164:6349-6358.
43. Whitmarsh A.J., Davis R.J. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 1996, 74:589-607.
44. Sizemore N., Leung S., Stark G.R. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol. Cell. Biol. 1999, 19:4798-4805.